Literature DB >> 19542757

Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome.

G Targher1, E Solagna, F Tosi, R Castello, G Spiazzi, G Zoppini, M Muggeo, C P Day, P Moghetti.   

Abstract

BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) are both associated with insulin resistance.We assessed whether NAFLD is associated with impaired insulin sensitivity in PCOS women independently of age and total adiposity. SUBJECTS AND METHODS: We enrolled 14 young PCOS women with NAFLD, 14 women with PCOS alone and 14 healthy controls, who were matched for age, body mass index, and total body fat (by bio-impedance analyzer). NAFLD was diagnosed by the surrogate measure of abnormal serum alanine aminotransferase (ALT) concentrations (defined as ALT>19 U/l) after excluding other secondary causes of liver disease (alcohol, virus, and medications). Insulin sensitivity was measured by euglycemic hyperinsulinemic clamp.
RESULTS: Insulin sensitivity was markedly decreased (p<0.001) in PCOS women with abnormal ALT levels, whereas it was similar between PCOS women with normal ALT levels andmatched healthy controls (8.3+/-2.5 vs 12.1+/-1.7 vs 13.2+/-1.8 mg/min x kg of fat-free mass, respectively). PCOS women with abnormal ALT levels also had higher plasma triglycerides and lower HDLcholesterol concentrations than those with PCOS alone. There was a strong inverse association between serum ALT levels and insulin sensitivity in the whole group of PCOS women (r=-0.59, p=0.0013).
CONCLUSIONS: Abnormal serum ALT levels, as surrogate measure of NAFLD, are closely associated with impaired insulin sensitivity in young PCOS women in a manner that is independent from the contribution of age and total adiposity. Early recognition of NAFLD by radiological imaging tests in this group of young patients is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542757     DOI: 10.1007/BF03345743

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

Review 1.  From fat to inflammation.

Authors:  Christopher Paul Day
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.

Authors:  P Moghetti; F Tosi; R Castello; C M Magnani; C Negri; E Brun; L Furlani; M Caputo; M Muggeo
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

Review 4.  Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.

Authors:  Roger K Schindhelm; Michaela Diamant; Jacqueline M Dekker; Maarten E Tushuizen; Tom Teerlink; Robert J Heine
Journal:  Diabetes Metab Res Rev       Date:  2006 Nov-Dec       Impact factor: 4.876

5.  Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment.

Authors:  Catherine Marin DeUgarte; Alfred A Bartolucci; Ricardo Azziz
Journal:  Fertil Steril       Date:  2005-05       Impact factor: 7.329

6.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

7.  Abnormal aminotransferase activity in women with polycystic ovary syndrome.

Authors:  Jeffrey B Schwimmer; Omid Khorram; Vicki Chiu; Walter B Schwimmer
Journal:  Fertil Steril       Date:  2005-02       Impact factor: 7.329

8.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

Authors:  Kevin M Korenblat; Elisa Fabbrini; B Selma Mohammed; Samuel Klein
Journal:  Gastroenterology       Date:  2008-01-30       Impact factor: 22.682

9.  Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Maya Gambarin-Gelwan; Sanjiv V Kinkhabwala; Thomas D Schiano; Carol Bodian; Hsu-Chong Yeh; Walter Futterweit
Journal:  Clin Gastroenterol Hepatol       Date:  2007-02-06       Impact factor: 11.382

Review 10.  Fatty liver: a novel component of the metabolic syndrome.

Authors:  Anna Kotronen; Hannele Yki-Järvinen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-09       Impact factor: 8.311

View more
  15 in total

Review 1.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Stavroula A Paschou; Stergios A Polyzos; Panagiotis Anagnostis; Dimitrios G Goulis; Christina Kanaka-Gantenbein; Irene Lambrinoudaki; Neoklis A Georgopoulos; Andromachi Vryonidou
Journal:  Endocrine       Date:  2019-09-19       Impact factor: 3.633

Review 3.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

Review 4.  Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Carly E Kelley; Ann J Brown; Anna Mae Diehl; Tracy L Setji
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

5.  Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile.

Authors:  Sara F Michaliszyn; Sojung Lee; Hala Tfayli; Silva Arslanian
Journal:  Fertil Steril       Date:  2013-09-11       Impact factor: 7.329

6.  The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep.

Authors:  Kirsten Hogg; Charlotte Wood; Alan S McNeilly; W Colin Duncan
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

7.  Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome.

Authors:  Susanne Tan; Nils Vollmar; Sven Benson; Jan-Peter Sowa; Lars P Bechmann; Guido Gerken; Dagmar Fuhrer; Ali Canbay
Journal:  Int J Endocrinol       Date:  2015-03-19       Impact factor: 3.257

Review 8.  Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis.

Authors:  Mahdi Ramezani-Binabaj; Mohsen Motalebi; Hamidreza Karimi-Sari; Mohammad Saeid Rezaee-Zavareh; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-11-01       Impact factor: 0.660

9.  Prevalence of hepatic steatosis in women with polycystic ovary syndrome.

Authors:  Ritu Karoli; Jalees Fatima; Ashok Chandra; Uma Gupta; Faraz-Ul Islam; Gagandeep Singh
Journal:  J Hum Reprod Sci       Date:  2013-01

10.  Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.

Authors:  Salvatore Petta; Alessandro Ciresi; Jessica Bianco; Vincenzo Geraci; Roberta Boemi; Luigi Galvano; Franco Magliozzo; Giovanni Merlino; Antonio Craxì; Carla Giordano
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.